(Boursier.com) — Stemcis, subsidiary ofHybrigenics SA, announces the conclusion of a strategic partnership with Dr. Yves Depaepe, orthopedic surgeon specializing in the treatment of osteoarthritis operating at Ghent Hospital in Belgium.
According to the WHO (World Health Organization), more than 130 million people will suffer from a form of osteoarthritis by 2050. 80% of these patients will have reduced mobility and 25% of them will be unable to perform daily activities.
Thanks to its MYFILL kit, Stemcis provides an innovative solution that makes it possible to sample and purify adipose tissue in the context of an autologous transplant. MYFILL is specifically designed for very small volumes of fatty tissue. This kit contains all the elements necessary for the surgeon to perform the operation. The surgical procedure, lasting about twenty minutes and requiring only local anesthesia, ensures a fat retention rate of between 70% and 90%. Thus, the patient benefits from a healthy adipose tissue graft, non-inflammatory, and free of impurities.
The results obtained are lasting and effective over several years depending on the form of osteoarthritis.
This protocol offers patients a therapeutic alternative whose results demonstrate a risk benefit greater than current treatments.
©2022 Boursier.com